

OncoTherapy Science, Inc.

MAY 24.2013

Announcement of the acquisition of sole rights to obtain patents for results derived from the collaborative research with Kumamoto University

OncoTherapy Science, Inc. (President & CEO: Takuya Tsunoda; hereinafter, OncoTherapy) has been collaborated with Kumamoto University (President: Isao Taniguchi; hereinafter, Kumamoto University). OncoTherapy announces that both parties entered into an agreement that OncoTherapy acquires the sole worldwide rights to obtain patents for results derived from the collaborative research.

The inventions that OncoTherapy has acquired the rights from Kumamoto University under this agreement are related to the peptide vaccines potentiating immune responses to cancer, which is expected to be a promising drug for cancer treatment. Furthermore, these peptide vaccines are expected to increase the potency of cancer peptide vaccines that are now under development by OncoTherapy when used in combination.